Rating Change
Oppenheimer analysts initiated coverage on Palisade Bio, Inc. (NASDAQ:PALI) with a Outperform rating on July 23, 2026.
new coverageNASDAQ:PALI
Oppenheimer Initiates Coverage on Palisade Bio, Inc. (PALI) with Outperform
Rating Change Oppenheimer analysts initiated coverage on Palisade Bio, Inc. (NASDAQ:PALI) with a Outperform rating on July 23, 2026. Market Context Palisade Bio, Inc.
Market Context
Palisade Bio, Inc. operates in the Healthcare sector. The stock currently trades at $1.99 with a market capitalization of $327.1M.
Analyst coverage from Oppenheimer provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Palisade Bio, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Palisade Bio, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 23, 2026 | Oppenheimer | Outperform | N/A |
| Apr 09, 2026 | Wolfe Research | Outperform | N/A |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | N/A |
| Feb 25, 2026 | Stifel | Buy | N/A |
| Jan 09, 2026 | B. Riley Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PALI Stock Page
Frequently Asked Questions
What does a Outperform rating mean for PALI?
A Outperform rating from Oppenheimer reflects the analyst's outlook on Palisade Bio, Inc. (NASDAQ:PALI). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PALI forecast page.